BioInvent International (BINV) Stock Overview
A clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BINV from our risk checks.
BINV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 22.60 |
| 52 Week High | SEK 41.60 |
| 52 Week Low | SEK 19.22 |
| Beta | 0.023 |
| 1 Month Change | -6.42% |
| 3 Month Change | 4.87% |
| 1 Year Change | -43.71% |
| 3 Year Change | 27.25% |
| 5 Year Change | -53.86% |
| Change since IPO | -98.29% |
Recent News & Updates
Recent updates
Immuno Oncology Combinations And Orphan Designations Will Reshape Long Term Prospects
Catalysts About BioInvent International BioInvent International is a biotech company focused on developing antibody based immuno oncology therapies targeting both hematologic malignancies and solid tumors. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About BioInvent International's (STO:BINV) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Investors Don't See Light At End Of BioInvent International AB (publ)'s (STO:BINV) Tunnel And Push Stock Down 26%
BioInvent International AB (publ) ( STO:BINV ) shareholders won't be pleased to see that the share price has had a very...BioInvent International AB (publ)'s (STO:BINV) CEO Might Not Expect Shareholders To Be So Generous This Year
Key Insights BioInvent International will host its Annual General Meeting on 29th of April Salary of kr2.96m is part of...Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, BioInvent...We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
The BioInvent International AB (publ) ( STO:BINV ) share price has fared very poorly over the last month, falling by a...Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
BioInvent International AB (publ) ( STO:BINV ) shareholders will have a reason to smile today, with the analysts making...Shareholder Returns
| BINV | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.2% | -0.9% | 0.9% |
| 1Y | -43.7% | 21.3% | 9.7% |
Return vs Industry: BINV underperformed the Swedish Biotechs industry which returned 21.3% over the past year.
Return vs Market: BINV underperformed the Swedish Market which returned 9.7% over the past year.
Price Volatility
| BINV volatility | |
|---|---|
| BINV Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BINV has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BINV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 112 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin’s lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA.
BioInvent International AB (publ) Fundamentals Summary
| BINV fundamental statistics | |
|---|---|
| Market cap | SEK 1.49b |
| Earnings (TTM) | -SEK 335.45m |
| Revenue (TTM) | SEK 217.86m |
Is BINV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINV income statement (TTM) | |
|---|---|
| Revenue | SEK 217.86m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 217.86m |
| Other Expenses | SEK 553.31m |
| Earnings | -SEK 335.45m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 27, 2026
| Earnings per share (EPS) | -5.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -153.98% |
| Debt/Equity Ratio | 0% |
How did BINV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/27 05:53 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInvent International AB (publ) is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |
| John Savin | Edison Investment Research |